Giant cell tumor (GCT) of bone accounts for approximately 6% of all primary bone tumors. 1 Although GCT is considered a histologically benign tumor, its local recurrence rate is as high as 8-62% after primary surgical resection, and >5% GCT patients develop pulmonary metastasis. [2] [3] [4] Besides rapid growth, severe osteolytic destruction is labeled as one of the key features of GCT. Drugs that inhibit osteolysis including bisphosphonate 3, 4 and denosumab, a nuclear factor j-B ligand (RANKL) antibody, 5, 6 could significantly inhibit the progression of GCT. GCT is characterized by osteoclast-like giant cells and their precursors, mononuclear stromal cells (GCTSCs), a key mediator of osteoclast activation. 6 GCTSCs are considered as the only proliferating population and represent the neoplastic component of GCT. 7 By secreting a series of cytokines such as RANKL and M-CSF, GCTSCs stimulate giant cell formation and osteoclast differentiation, which further induces bone resorption. 7, 8 Transforming Growth Factor-beta (TGF-b) is a significant factor in bone remodeling and tumor-bone microenvironment by stimulating early osteoblast proliferation, inhibiting late stage osteoblast differentiation and mineralization, 9, 10 and promoting bone catabolism through stimulation of RANKL secretion and enhancement of osteoclast survival. 11, 12 Bone functions as one of the main repository for TGF-b, which stores in a latent form (LTGF-b) in bone matrix and can be released and activated during osteoclastic resorption. 13 Besides its effect on the bone, TGF-b could also promote tumor progression by the controlling of over proliferation, loss of apoptotic response, epithelial-to-mesenchymal transition (EMT) and sustained angiogenesis. 14 Lou et al. 15 reported that TGF-b played an important role in tumor progression and osteolysis of GCT via Smad3. But the detailed molecular mechanisms underlying the effect of TGF-b in GCT still remain to be characterized.
The Protease activated receptor (PAR) family consists of four members, PAR-1, 2, 3 and 4, of which PAR-1 is the prototype. PAR-1 is recognized as a main receptor for thrombin, 16 but several other cytokines have also been reported as the activators of PAR-1, including TGF-b, matrix metalloproteinase 1 (MMP1), MMP2, Kallikrein-related peptidase 6 (KLK6), tissue factor (F3) and coagulation factor VII (F7). [17] [18] [19] [20] [21] The increased expression of PAR-1 has been reported to be correlated with tumor progression in breast, lung, prostate, and gastric cancers by promoting cell proliferation, invasion and angiogenesis through the regulation of NF-kappaB and ERK1/2 pathways. 17, [22] [23] [24] [25] Recent study 26 also showed that PAR-1 played a critical role in bone remodeling, as represented by increased bone mass and trabecular thickness and decreased bone resorption marker protein in PAR-1 knockout mice. Wilson et al. 27 further showed that activation of PAR-1 promoted chemotaxis of osteoclast precursors in vitro and increased both osteoclast precursors and osteoclasts at the tumor-bone interface of breast cancer. These findings suggested that PAR-1 may play a critical role in bone tumors. However, the roles and mechanisms of PAR-1 in tumor-induced osteoclastogenesis and osteolysis remain unclear.
In the present study, we detected the expression of PAR-1 and its activators in GCT of bone and further explored the regulatory mechanism of TGF-b in PAR-1 expression. The expression of PAR-1 in microvesicles (MVs) from GCTSCs were also examined. Using the PAR-1 knockout GCTSCs, we detected the role of PAR-1 in cell proliferation, angiogenesis and osteoclast differentiation. At last, microarray assay was performed to predict the downstream of PAR-1 in GCT of bone.
Material and Methods

Clinical samples and cell culture
Fifty six GCT samples were collected from patients aged 21-58 years who underwent surgical resection for primary GCT in our hospital between January 2013 and June 2014 (Supporting Information Table 1 ). Patients who received radiotherapy (n 5 2), bisphosphonate treatment (n 5 7) or both radiotherapy and bisphosphonate treatment (n 5 5) before operation, or had co-existing diabetes mellitus (n 5 1), rheumatoid arthritis (n 5 1) or other diseases that may affect bone metabolism were excluded from the analysis. Thus, a total of 40 clinical samples were included in this study. The para-tumor tissues from the same GCT patients were used as normal controls. Samples were snap-frozen and stored in liquid nitrogen within 2 hr after surgical excision.
This study was approved by the Ethnic Committee of Changzheng Hospital of the Second Military Medical University (Shanghai, China), and written informed consent was obtained from all participants.
Cell culture
For primary cell culture, bone marrow macrophages (BMMs) isolated from C57/BL6 mice and GCTSCs isolated from GCT samples were cultured as described previously. 8 Bone marrow mesenchymal stem cells (BMSCs) were isolated from the bone marrow of the same GCT patients as described previously. 28 BMMs and GCTSCs were maintained in a-MEM supplemented with 10% fetal bovine serum (FBS) in the cell incubator (378C, 5% CO2). BMSCs were cultured in DMEM/F-12 supplemented with 10% FBS. Human umbilical vein endothelial cells (HUVECs) and HEK293 CELLS were purchased from the American Type Culture Collection (Manassas, VA) and cultured in EGM-2 and DMEM with 10% FBS, respectively.
qRT-PCR
Total RNA was isolated using TRIZOL (Invitrogen, Carlsbad, CA) and reverse transcribed into cDNA using the PrimeScript TM RT Master Mix (Takara, Shiga, Japan). Gene transcripts were quantified on 7900HT Fast Real-Time PCR System (Life Technologies Corporation, Carlsbad, CA) using SYBR V R Premix Ex Taq TM II (Takara). All primers were listed in Supporting Information Table 2 .
Immunohistochemical (IHC) staining
The tissue sections were stained with hematoxylineosin and by IHC using indirect immunoperoxidase technique. The antibody of human PAR-1 (ab32611) was purchased from Abcam (Cambridge, UK), and the antibodies of PAR-2 (sc-13504), PAR-3 (sc-5598) and PAR-4 (sc-1666), TGF-b (sc-7892), MMP1 (sc-21731), MMP2 (sc-13595), KLK6 (sc-374564), F3 (sc-20160) and F7 (sc-16343) were brought from Santa (Santa Cruz, CA). MMP3 antibody (AF0217) was purchased from Affinity Biosciences (OH). The IHC stains were assessed independently by three observers who had no knowledge about the specimen characteristics.
What's new? Protease activated receptor 1 (PAR-1) is overexpressed in several tumors and also plays a critical role in bone remodeling. Here the authors find PAR-1 overexpressed in giant cell tumor of bone and uncover a critical upstream role of TGF-b in PAR-1 overexpression. Inhibition of PAR-1 suppressed tumor growth, angiogenesis and osteoclastogenesis in giant cell tumor models both in vitro and in vivo, implicating PAR-1 causally in this generally benign condition that exhibits a high local recurrence rate.
Western blot and ELISA
Western blot assay for PAR-1, PAR-2, PAR-3, PAR-4, TGFb, MMP1, MMP2, KLK6, F3 and F7 was performed using the antibodies described in IHC staining. Mouse PAR-1 (sc-13503) antibody was purchased from Santa Cruz. Beta-actin protein was determined using the specific antibody (Santa) as a loading control. ELISA assay was performed with the ELISA kit (Uscn Life Science, Wuhan, China) for human PAR-1 following the manufacturer's instructions.
Immunofluorescence (IF) staining
IF staining was performed using the antibody of PAR-1 (Abcam) and EEA1 (22266-1-AP, Proteintech, IL) following the protocol reported previously. 13 The signals of IF were examined with a BX51 fluorescence microscope (Olympus, Tokyo, Japan).
Luciferase reporter assay pGL3-basic plasmid was enzyme digested by KpnI and XhoI (TransGen Biotech, Beijing, China). The possible promoter region of PAR-1 (-2,000 0 bp from the initiation codon) was synthesized by GENEWIZ Inc (Suzhou, China) and inserted into pGL3-basic using the Quick-Fusion Cloning Kit (Biotool, Houston, TX). The overexpression (OE) plasmids of Smad3 and Smad4 were purchased from Vigene Biosciences (Jinan, China). Dual luciferase assays were conducted in a 24 well plate format. pGL3-PAR1-promoter report 1 TK100 Renilla report were transfected into 60% confluent HEK293 cells, along with OE-Smad3 or OE-Smad4 plasmids or negative control. After 48 hr transfection, firefly and renilla luciferase were quantified sequentially using the Dual Luciferase Assay kit (Promega, Madison, WI) following the manufacturer's recommendations.
SEM and TEM
The morphological characterization of the MVs from GCTSCs was performed by scanning electron microscopy (SEM) using a Hitachi U8010 microscope operated at 3 kV and a Tecnai G2 20 TWIN transmission electron microscope (TEM) operated at 100 kV.
Isolation of microvesicles (MVs)
GCTSCs and BMSCs at 80% confluence were washed three times with PBS, added to a-MEM containing 1% FBS which had been previously filtered three times with a 0.1-lm poresize filter (Millipore, Boston, MA) before use. After 24 hr cultivation, MVs were collected from the supernatants using exoEasy Maxi Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions.
PKH26 labeling and flow cytometry
GCTSCs were labeled with PKH26 (Sigma, St Louis, MO) according to the manufacturer's protocol. The labeling reaction was terminated by adding an equal volume of 1% BSA. Red fluorescence of monocytes was detected by flow cytometry (Beckman Coulter Inc, Fullerton, CA).
Construction of stable knockout cell lines using TALENs
The plasmids of TALENs for PAR-1 gene were designed and constructed using Fast TALETM TALEN Assembly kit from SiDanSai biotechnology (Shanghai, China). To validate the activities of synthesized endonucleases, an equal amount of expression vectors for the left and right TALENs or sgRNA were transferred into HEK293 cells. The most activated pair of TALENs were transfected into GCTSCs. After selection with puromycin, resistant colonies were picked up and examined by genomic PCR and gene sequencing.
Proliferation assay. Cells were seeded in 96-well plates (5 3 10 3 per well) and cultured for 0, 24, 48 and 72 hr and assessed using the Cell Counting Kit 8 (CCK8, Biotool). Results were measured by absorbance at 450 nm using an ELx800 microplate reader (BioTek Instruments, Winooski, VT).
Tube formation assay
Fifty microliter of chilled Matrigel (BD Bioscience, Franklin Lakes, NJ) was added to a 96-well plate and incubated at 378C for 30 min. HUVECs (1 3 10 4 cells) were suspended in 100 ll of EBM-2 and conditioned medium from GCTSCs or PAR-1 knockout GCTSCs, and added to the solidified Matrigel. After 18 hr incubation, angiogenesis was assessed on the basis of capillary-like structure formation. Tubes in randomly chosen five microscopic fields were photographed and counted.
Tartrate resistant acid phosphatase (TRAP) staining and actin ring formation
For TRAP staining, cells were fixed and stained using the TRAP staining kit (Sigma). TRAP-positive multinucleated cells containing three or more nuclei were counted as mature osteoclasts. For actin ring formation assay, cultured BMMs were first fixed with 4% PFA in PBS for 10 min, permeabilized with 0.1% Triton-X 100 in PBS for 5 min, and then incubated with rhodamine-conjugated phalloidin (Molecular Probes, Eugene, OR). The ring structure of F-actin dots that indicates osteoclastogenesis was observed under a fluorescence microscope.
Chick CAM model construction
A short-term model of GCT in vivo was set up in the chick CAM as described previously. 29 BrefFertilized white leghorn chicken eggs (Valo-SPF eggs, LohmannTierzucht GmbH, Cuxhaven, Germany) were incubated at a humidity of 70% and 378C. At embryonic Day 3, 2-3 ml albumen was removed with a syringe. After 10-day incubation, small plastic rings made of Thermanox TM cover discs were placed on the CAM. After gentle laceration of the CAM surface, 20 ll re-suspended tumor suspension with 2lg PAR-1 antibodies (PAR-1 Ab, Abcam) or PBS was deposited into the rings. PAR-1 antibodies or PBS was injected additionally at Day 13. Until Day 16, CAMs were measured and collected for further analysis. All embryos that died before Day 16 were excluded from further analysis. Microvessel density was determined by CD31 staining using Weidner capillary counting method. 30 
Microarray assay
Total RNA was extracted from GCTSCs using TRIZOL (Invitrogen). The concentration of the RNA was analyzed using the NanoDrop2000 (Thermo Scientific, Wilmington, MA). Microarrays were performed by utilizing the GeneChip V R Human Transcriptome Array 2.0 (Affymetrix, Santa Clara, CA) according to the manufacturer's instructions. Raw data were corrected by background subtraction, and then normalized within and between each array. The differentially expressed genes and alternatively spliced genes were analyzed by Affymetrix Transcriptome Analysis Console software. Statistical comparisons were performed by analysis of variance.
Statistics SPSS 19.0 statistical software (SPSS Inc, Chicago, IL) was used for statistical analysis. All data are presented as mean 6 standard error of the mean. The comparison of IHC staining between groups were performed by v 2 test. Statistics of the mean value between groups were assessed using independent Student's t test, assuming double-sided independent variance. All experiments were repeated at least three times, and representative experiments are shown. P values 0.05 were considered statistically significant.
Results
PAR-1 is upregulated in GCT of bone
The qRT-PCR assay showed that the mRNA level of PAR-1 was significantly upregulated in GCT tissues, while there was no significant fluctuation and difference in PAR-2, -3 and -4 mRNA expression between GCT and para-tumor tissues (Fig.  1a) . IHC staining of the 40 GCT and para-tumor tissues showed that PAR-1 was overexpressed in GCT (Fig. 1b) , while the expression of PAR-2, -3 and -4 exhibited no clear changes (Fig. 1c) . Western blot assay also confirmed the overexpression of PAR-1 in GCT tissues (Fig. 1d) . Knowing that GCTSCs are the only neoplastic component of GCT, we further isolated GCTSCs and BMSCs from the GCT patients for further experiments. The result of Western blot assay showed that PAR-1 but not PAR-2, -3 and -4 was overexpressed in GCTSCs compared with that in BMSCs, which is consistent with them in GCT tissues (Fig. 1e) . IF staining also confirmed that PAR-1 was upregulated in GCTSCs and mainly expressed in cellular cytoplast and membrane (Fig. 1f) .
TGF-b promotes the expression of PAR-1 through Smad pathway
Knowing that multiple cytokines, including TGF-b, MMP1, MMP2, KLK6, F3 and F7, are the activators of PAR-1, we further detected the expression of these genes in GCT of bone to see which cytokines might play the main role in PAR-1 overexpression in GCT. IHC staining showed that TGF-b, MMP1, MMP2, KLK6, F3 and F7 were all expressed in both giant cells and GCTSCs (Fig. 2a) , while western blot assay showed that only TGF-b and F3 were obviously overexpressed in GCTSCs compared with BMSCs (Fig. 2b) . MMP3 was known as an activator of TGF-b. 31 Through IHC staining, we found that both MMP3 and TGF-b were upregulated in GCT tissues compared to para-tumor tissues (Supporting Information Figure 1 A and B) . Furthermore, a statistical correlation was observed between MMP3 and TGFb expression, and PAR-1 expression was also correlated to TGF-b. But perhaps limited to the sample size, no statistical correlation was observed between MMP3 and PAR-1 expression (Supporting Information Figure 1 C-E) .
TGF-b have shown its key roles in tumor-bone microenvironment, but the mechanism of TGF-b induced PAR-1 overexpression have not been reported. We found that TGF-b (10 ng/ mL, Peprotech, Rocky, CT) significantly upregulated the expression of PAR-1 in a time-dependent manner (Fig. 2c) , while the inhibitor of TGF-b receptor, LY2109761 (10 lM, Santa), could obviously reduced the stimulation role of TGF-b in PAR-1 expression (Fig. 2d) . To further examine PAR-1 activation after TGF-b stimulation, we detected the expression of PAR-1 and EEA1, a marker of internalization which is considered as one effect of PAR-1 activation, 32 through IF assay. The results showed that TGF-b upregulated the expression of PAR-1 and EEA1, and also promoted the co-location of PAR-1 and EEA1 (Supporting Information Figure 2 A The Smad pathway is considered as the main downstream signaling of TGF-b, and the Smad2/3/4 complex works as a transcription factor. Thus, we detected the roles of Smad3 and Smad4 in PAR-1 transcription using dual luciferase reporter assay system. The results showed that both Smad3 and Smad4 could clearly increase the ratio of firefly to renilla fluorescence (Fig. 2e) . In addition, a total of 4 possible Smad-binding elements (SBEs, CAGAC 33 ) were detected in the promoter region of PAR-1 using bioinformatics analysis (Supporting Information Figure 3 ). These results indicated that TGF-b possibly stimulated PAR-1 expression through the activation of Smad3 and Smad4.
MVs may participate in the transport of PAR-1 between GCTSCs and monocytes
MVs are fragments of the plasma membrane ranging from 100 to 1,000 nm secreted from cells. They are believed to be involved in the communication between osteoblast and osteoclast precursors, which further induces osteoclastogenesis. 34 Because of the lack of information about MV secretion in GCTSCs, we used both SEM and TEM to observe the existence of MVs from GCTSCs. It was found that MVs were secreted from GCTSCs (Figs. 3a and 3b) . ELISA assay was used to detected the expression of PAR-1 in MVs. The results showed that PAR-1 was upregulated in MVs from GCTSCs as compared with that from BMSCs (Fig. 3c) . Western blot assay also confirmed that PAR-1 but not PAR-2, 3 and 4 was increased in GCTSC-derived MVs (Fig. 3d) .
PAR-1 activation has been confirmed to play an important role in the recruitment of monocytes, 27 which are also considered as the osteoclast precursor. In this study, we wondered whether MVs derived from GCTSCs containing PAR-1 could also be accepted by osteoclast precursors. We labeled GCTSCs with a red fluorescent dye PKH26 or its solvent as the negative control and cultured for 24 hr. Then, the MVs derived from GCTSCs were collected and added into the culture medium of RAW264.7 cells. After 24 hr, RAW264.7 cells were observed under the fluorescence microscope. The results showed that RAW264.7 cells were obviously stained with red fluorescence while there was no significant change in the control cells (Fig. 3e) . The result of flow cytometry of RAW264.7 cells stimulated with MVs also showed the similar result (Fig. 1f) . These results suggest that MVs might participate in the transport of PAR-1 from GCTSCs to monocytes.
Knockout of PAR-1 inhibits GCTSC proliferation and angiogenesis
To further investigate the role of PAR-1 in GCTSCs, we established a PAR-1 knockout GCTSC cell line using TALENs. Three left TALEN plasmids and two right TALEN plasmids were constructed and the target sites are shown in Supporting Information Figure 4 A. The activities of each two TALEN constructs were examined by SSA assay, and construct L1-R1 showed the highest activity among the constructs in the assay (Supporting Information Figure 4B ). Then, construct L1-R1 was introduced into GCTSCs and one of the clones with out-of-frame deletion was picked out. Western blot was used to confirm the absent expression of PAR-1 in the knockout GCTSCs (Supporting Information Figure 4 C) .
Next, we examined the proliferation rate of WT and PAR-1
2/2
GCTSCs using CCK8 assay. The result showed that the proliferation of PAR-1 2/2 GCTSCs was downregulated significantly compared with WT GCTSCs, while there was no significant difference in the number of WT and PAR-1 2/2 GCTSCs after 48 hr of culture (Fig. 4a) . Tube formation assay was performed to investigate the role of PAR-1 in GCTSC-induced angiogenesis. The conditioned medium from WT and PAR-1 2/2 GCTSCs was used in the culture of HUVECs. After 24 hr, conditioned medium from WT GCTSC induced HUVECs formed organized elongated tube-like structures that resembled capillaries with a network, while HUVECs in conditioned medium from PAR-1 2/2 GCTSCs exhibited an incomplete network of capillary-like structures (Fig. 4b) .
Knockout of PAR-1 inhibits GCTSC-induced osteoclast differentiation
The effect of PAR-1 in tumor induced osteoclast differentiation has rarely been reported. In the present study, we selected BMMs with M-CSF stimulation as an in vitro osteoclast differentiation model. WT and PAR-1 2/2 GCTSCs conditioned medium were used as different stimuli during osteoclastogenesis. Two groups of BMMs were cultured with the conditioned medium from WT or PAR-1 2/2 GCTSCs containing M-CFS (10 ng/mL). Seven days later, BMMs treated with the conditioned medium of PAR-1 2/2 GCTSCs showed much less formation of TRAP-positive multinucleated osteoclasts compared with the control (Fig. 4c) . The mRNA levels of NFATC-1, TRAP and cathepsin K (CTSK) were detected by qRT-PCR, knowing that NFATC-1, TRAP and CTSK are all markers of osteoclasts. 35 The results showed that the mRNA levels of NFATc1, TRAP and CTSK were all significantly downregulated in PAR-1 2/2 GCTSCs conditioned medium stimulated BMMs (Figs. 4df) . The result of actin ring formation assay, another obvious characteristic of mature osteoclasts during osteoclastogenesis and a prerequisite for osteoclast bone resorption, 8 also supported that knockout of PAR-1 in GCTSCs suppressed GCTSC-induced osteoclastogenesis markedly (Fig. 4g) . In addition, the MVs from PAR-1 2/2 or WT GCTSCs were also used in BMM cell culture. After 7 days stimulation, we found that MVs from PAR-1 2/2 GCTSCs showed much weaker effects on osteoclast differentiation compared to those from WT GCTSCs through TRAP staining assay and qRT-PCR of NFATC-1, TRAP and CTSK (Supporting Information Figure 5 ).
PAR-1 regulates GCT growth, angiogenesis and giant cell formation in vivo
Due to the limited proliferation ability and complex composition of GCT, it is difficult to perform an in vivo experiment of GCT. The chick CAM model of GCT is the only reported animal model of GCT at present. 29 In this study, we constructed this model to observe the effect of PAR-1 in GCT in vivo. Tumor cells with PAR-1 Ab or PBS were injected into the CAM and incubated for six days. Then, the CAMs were picked out and the tumors in CAM were measured. H&E staining and CD31 staining were performed to investigate giant cell formation and angiogenesis. The results showed that the tumors injected with PAR-1 Ab were significantly smaller than those in the control group (Figs. 5a and 5b) . H&E staining also showed less giant cell formation after PAR-1 Ab stimulation (Figs. 5c and 5d ). In addition, much less CD31 positive cells were observed in the tumors with PAR-1 Ab, indicating that inhibition of PAR-1 suppressed angiogenesis in GCT in vivo (Figs. 5e and 5f ).
Possible downstreams of PAR-1 in GCT of bone RANKL/OPG system plays the key role in osteoclastic resorption. 36 To investigate the mechanism of PAR-1 induced osteoclastogenesis, we stimulated GCTSCs with the activating peptide of PAR-1 (PAR-1-AP, 10 lM and 20 lM) for 6 hr. Using qRT-PCR assay, we found that the mRNA level both RANKL and OPG were increased after PAR-1-AP stimulation (Supporting Information Figure 6 A and B), but the ratio of RANKL/OPG showed no significant change (Supporting Information Figure 6 C), which indicated that PAR-1 might regulate osteoclastogenesis in an RANKL/OPG independent pathway.
To gain further insights into the mechanism of PAR-1 in GCT of bone, we performed microarray assay in GCTSCs stimulated with or without PAR-1-AP. The results showed that 799 genes were downregulated, and 442 genes were upregulated after PAR-1 activation (Fig. 6a) . A number of genes that related with tumor progression and osteoclastic destruction were upregulated after PAR-1-AP stimulation, and part of the results were listed in Figure 6b and Supporting Information Table 3 . The evaluation of genes involved in osteolysis including PTGS2, IL8, JUN and FOS were further verified (Figs. 6cf) , while part of the other genes functioned in tumor growth and angiogenesis were also repeated by qRT-PCR, such as ATF4, VEGFA, CYR61, SNAI1 et al. (Supporting Information Figure 7) . These results might partly explain the mechanism of PAR-1 in tumor progression and bone destruction in GCT of bone.
Discussion
The PAR family contains four members (PAR-1 to -4) that are characterized by a unique activation mechanism that removal of the N-terminal extracellular region releases a new tethered ligand that interacts with the body of the receptor to induce transmembrane signaling, thereby triggering a range of signaling pathways affecting multiple pathophysiological responses. 37 However, the expression of PARs in GCT remains unclear. In the present study, we found that PAR-1 to PAR-4 were all expressed in GCT, but only PAR-1 was overexpressed in GCT as compared with that in the normal tissue. In addition, one of the activators of PAR-1, TGF-b were upregulated in GCT, and could stimulate the expression of PAR-1 in GCTSCs, which possibly achieved by promoting the transcription of PAR-1 through activating Smad3 and Smad4. Meanwhile, we showed that knockout of PAR-1 inhibited tumor growth, angiogenesis and osteoclastogenesis both in vitro and in vivo. Previous studies 13, 38 have confirmed that osteoclastic destruction could release and activate TGF-b stored in bone matrix, which would further activate PAR-1 in GCTSCs, fueling the cycle (Fig. 6g) .
MVs exert a wide range of biological functions in cell-cell communications and thus participate in diverse pathophysiologic processes, including tumor progression. 39 But limited information is available regarding the function of tumoral MVs on osteoclast differentiation and bone destruction, and the role of MVs in GCT of bone has also rarely been reported. PAR-1 was detected in platelet-derived MVs 40 and PAR-1-AP significantly increased the release of MVs from platelets. 41 In this study, we found that PAR-1 was also expressed in GCTSC-derived MVs and was obviously upregulated compared with that in MSC-derived MVs. In addition, MVs from GCTSCs could be accepted by monocytes, indicating that MVs might be involved in the transportation of PAR-1 from GCTSCs to monocytes. Activation of PAR-1 in monocytes was confirmed as a positive factor in the process of osteoclastogenesis by promoting the osteoclast precursors migrating into the tumor-bone microenvironment. 27 Thus, PAR-1 transported by MVs may involve in monocytes differentiation to osteoclasts. PAR-1 has been shown to be overexpressed in prostate and breast cancer bone metastasis. 27, 42 But the mechanism of PAR-1 in bone destruction still needs further studies, and the role of PAR-1 in bone formation remains controversial. Aronovich et al. 43 reported that PAR-1 knockout mice showed decreased bone mineral density (BMD), bone volume over total volume (BV/TV) and trabecular number (Tb.N), while Tudpor et al. 26 exhibited that BMD, BV/TV and Tb.N were increased, and trabecular number/spacing (Tb.Sp) was decreased in PAR-1 KO mice as compared with the control. In the present study, we found that inhibition of PAR-1 in GCTSCs significantly inhibited osteoclast differentiation in vitro and giant cell formation in vivo. RANKL/OPG functions as one of the most important system in osteoclastic destruction. 36 However, we found that the ratio of RANKL/OPG showed no clear change after PAR-1-AP stimulation, which may have indicated that PAR-1 regulated osteoclastogenesis in RANKL/OPG independent pathways. Thus, microarray assay was performed to investigate the possible downstreams of PAR-1. The results showed that a number of genes involved in osteolysis were upregulated after PAR-1-AP stimulation, including PTGS2, IL8, JUN, FOS, XBP1, ANGPTL4, MCL1 and ATF4. These results may partly explain the mechanism of PAR-1 in tumor induced osteoclastic destruction.
GCT of bone is characterized by high local recurrence after treatment, with an overall recurrent rate of 37.3% after surgery in our previous study. 3 Recent studies have shown that drugs inhibited osteolysis could significantly suppress the recurrence of GCT, including denosumab and bisphosphonate. Our findings have shown a decreased recurrent rate in GCT patients treated with bisphosphonate after surgery, with the rate of 10.5%, 44 while Rekhi et al. reported the recurrent rate of 18.5% in GCT patients treated with denosumab. 45 Thus, tumor progression still could not be controlled in part of the GCT patients. PAR-1 has been shown to be overexpressed in several cancers, and play important roles in tumor progression. 17, [22] [23] [24] [25] In the present study, we found that the suppression of PAR-1 could significantly inhibited tumor growth and osteoclastogenesis both in vitro and in vivo, which possibly through RANKL independent pathways, indicated that therapy against PAR-1 might be a new supplement of denosumab. Recently, the U.S. Food and Drug Administration approved vorapaxar SCH530348 (Zontivity), a novel PAR-1 inhibitor to reduce the risk of myocardial infarction, stroke and cardiovascular death (TRACER; TRAP-2 P: TIMI 50). 46 But whether vorapaxar could inhibit tumor progression still need further study.
In conclusion, our study demonstrated that PAR-1 was upregulated in GCT of bone, and TGF-b might promote PAR-1 expression through the activation of Smad3 and Smad4 in GCTSCs. In addition, MVs were identified as possible transporters of PAR-1 from GCTSCs to monocytes. Furthermore, PAR-1 played a positive role in tumor cell proliferation, angiogenesis and osteoclastogenesis in GCT both in vitro and in vivo. Microarray assay was also performed to investigate the possible downstream of PAR-1 in GCTSCs. Altogether, our study for the first time identified the role of PAR-1 in GCT of bone, which may provide a new possible target for the diagnosis and treatment of GCT.
